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Context: Increasedbonefragility is a frequent complicationofhypercortisolismduepredominantly
to suppression of bone formation. Sclerostin is an osteocyte-produced negative regulator of bone
formation, which is up-regulated by glucocorticoids in mice.
Objective: Our objective was to assess the effect of endogenous hypercortisolism on circulating
sclerostin and bone turnover in humans.
Design: We measured sclerostin, -C-terminal telopeptide, amino-terminal propeptide of type 1
procollagen, and fibroblast growth factor 23 in blood samples of 21 patients with endogenous
hypercortisolism and 21 age- and gender-matched controls. In 12 patients, measurements were
repeated at various time intervals after successful surgical treatment (transsphenoidal surgery or
adrenalectomy).
Results: Plasma sclerostin levels were significantly decreased in patients compared with controls
(112  49 vs. 207  48 pg/ml, P  0.001). In the 12 patients who were evaluated after surgical
treatment, sclerostin levels increased from 121.4  46.5 to 175.8  78.5 pg/ml (P  0.003). These
changes in plasma sclerostin levelswere accompaniedby significant increases in levels of fibroblast
growth factor 23 (from 44.2  12.2 to 84.0  58.8 pg/ml, P  0.017) and of the bone turnover
markers amino-terminal propeptide of type 1 procollagen (from 31.718.2 to 94.2 92.2 ng/ml,
P  0.037) and -C-terminal telopeptide (from 134.2  44 to 409.2  285 pg/ml, P  0.005).
Conclusions: Contrary to the findings in mice, circulating sclerostin is decreased in patients with
chronic endogenous hypercortisolism and increases after treatment. These findings suggest that
in humans, chronic exposure toglucocorticoids affects thenumber or functionof osteocytes rather
than the production of sclerostin. (J Clin Endocrinol Metab 97: E1953–E1957, 2012)
Glucocorticoid excess increases bone loss and fragilityleading to glucocorticoid-induced osteoporosis (1,
2). The action of glucocorticoids on bone is complex and
involves local and systemic factors that adversely affect
bone mass and quality. Of these, suppression of bone for-
mation and increased rate of apoptosis of osteoblasts and
osteocytes are considered major determinants of the del-
eterious effect of glucocorticoids on bone.
In osteoblasts, glucocorticoids inhibit Wnt signaling (3,
4), a pathway essential for osteoblast proliferation, differen-
tiation, and survival; enhance the expression of receptor ac-
tivator of nuclear factor- B-ligand (RANKL); and reduce
that of osteoprotegerin promoting alsoosteoclast activity (5,
6). In recent years, the osteocyte-derived protein sclerostin
has emerged as a key inhibitor of the Wnt signaling path-
way in osteoblasts. In rodents, glucocorticoids stimulated
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the expression of SOST, the gene encoding sclerostin (3),
and a neutralizing antibody against sclerostin prevented
glucocorticoid-induced bone loss (7). These findings sug-
gest that glucocorticoids may exert their action on bone
formation by stimulating the production of sclerostin. In
the present study,we tested this hypothesis in humans. For
this, we studied patients with endogenous hypersecretion
of cortisol because in glucocorticoid-treated patients, dis-
ease-related factorsmay have independent effects on bone
metabolism and fragility andmay also affect the synthesis
of sclerostin (8, 9).
Patients and Methods
Patients
We studied 21 consecutive patients with endogenous hyper-
cortisolism. The diagnosis and causes of hypercortisolism were
established as previously described (10). Fifteen patients had
ACTH-producing pituitary adenomas, two had adrenal adeno-
mas, and four had ectopic ACTH production (two of unknown
origin, one neuroendocrine tumor, and one metastatic mela-
noma). Nonfasting blood samples were obtained from all pa-
tients at different times of the day, mainly in the afternoon.
In 12 of the 21 patients, blood samples were also obtained at
various time intervals after surgical treatment and achievement
of biochemical remission. Eight of these patients were treated by
transsphenoidal surgery and four by bilateral adrenalectomy.
Remissionwas establishedbyanadequate suppressionofplasma
cortisol after 1 mg dexamethasone overnight and disappearance
of clinical signs and symptoms of hypercortisolism postopera-
tively (10).At the timeofbloodcollection, eightof the12patients
were receiving substitution therapy with hydrocortisone (n 7)
or dexamethasone (n  1), and two patients used L-T4 for sec-
ondary hypothyroidism.
Preoperative levels of sclerostin and bone turnover markers
were compared with those of 21 age- and gender-matched
healthy volunteers who were recruited by advertisements. None
of these individuals used any medication or had any illness re-
quiring medical attention. Similar to patients, nonfasting blood
samples were obtained from controls in the afternoon.
All studied subjects (healthy and patients) had normal renal
function and serum calcium and phosphate concentrations.
Biochemical measurements
Creatinine was measured by semiautomated techniques. In-
tact PTH was measured by the Immulite 2500 (Siemens Diag-
nostics, Breda, TheNetherlands). Amino-terminal propeptide of
type 1 procollagen (P1NP) and -C-terminal telopeptide (CTX)
were determined by the E-170 system (Roche BV,Woerden, The
Netherlands). Sclerostin was measured by an electrochemilumi-
nescence assay (MSD 96-well MULTI-ARRAYHuman Scleros-
tin Assay; Meso Scale Discovery, Gaithersburg, MD), as previ-
ously described (11). With this assay, no sclerostin could be
detected in the serum of 19 patients with sclerosteosis, whereas
sclerostin was detectable in serum of 77 healthy individuals. In
previous studies,wemeasured sclerostin in serum,whereas in the
present study, we used EDTA plasma samples due to their avail-
ability. Because of earlier reported differences in sclerostin levels
in plasma and serum (12), we first measured sclerostin levels in
simultaneously obtained serum and plasma samples from 26
individuals with serum sclerostin levels ranging from 16.2–94.7
pg/ml. Compared with serum, sclerostin levels were on average
3.6-fold higher in plasma, but the two values were highly and
significantly correlated (r  0.91; P  0.001).
Fibroblast growth factor 23 (FGF23) levels, as an indepen-
dent index of osteocyte function, were measured with the Intact
FGF23 ELISA kit (Kainos Laboratories, Tokyo, Japan). The in-
tra- and interassay coefficients of variation were 9 and 11%,
respectively.
Statistical analysis
Values are reported as mean  SD, unless otherwise stated.
Differences betweenpatients and controlswere assessedby t test.
Of the 12 patients who were studied during biochemical remis-
sion, differences in sclerostin levels and other biochemical mark-
ers before and after surgical treatment were analyzed by paired
t tests. Correlations between markers and changes in markers
were assessed by Pearson’s correlation. Normality of distribu-
tion was assessed by Shapiro-Wilk tests. Levels of CTX and
FGF23 were log transformed because of skewness. Data were
analyzed using SPSS version 16.0 (SPSS Inc., Chicago, IL). A P
value 0.05 was considered significant.
Results
Baseline biochemistry
Group characteristics and relevant biochemical param-
eters at baseline in patients and controls are shown in
Table 1. Of the 21 patients with endogenous hypercorti-
solism included in the study, 16were female (11 premeno-
pausal and five postmenopausal) and five were male.
Mean age was 41.3  12.7 yr, mean weight 86.6  17.1
kg, and mean body mass index 31.2  6.6 kg/m2.
Mean plasma sclerostin levels were significantly lower
in patients compared with controls (112.0  49.0 vs.
207.2  48.4 pg/ml, P  0.001), whereas there were no
significant differences between the two groups in levels of
P1NP, CTX, or FGF23 (Table 1).
Meanafternooncortisol concentrationsof patientswas
0.63  0.31 mol/liter, and there was no relationship
between plasma cortisol and sclerostin levels(r  0.28;
TABLE 1. Demographics and baseline biochemical
parameters of patients with endogenous
hypercortisolism and age- and-gender matched healthy
controls
Controls Patients P value
Male/female 5/16 5/16
Age (yr) 41.6  11.8 41.3  12.7 0.66
P1NP (ng/ml) 44.9  14.3 36.9  21.9 0.12
CTX (pg/ml) 224  144 229  224 0.94
Sclerostin (pg/ml) 207  48 112  49 0.001
FGF23 (pg/ml) 37.5  16.9 42.8  12.1 0.25
Creatinine (mol/liter) 68.6  12.8 66.9  13.8 0.62
E1954 van Lierop et al. Sclerostin in Endogenous Hypercortisolism J Clin Endocrinol Metab, October 2012, 97(10):E1953–E1957
P 0.31) or P1NP (r 0.45; P 0.09); however, plasma
cortisol concentrations were significantly correlated with
serum CTX levels (r  0.65; P  0.009). Serum levels of
CTX and P1NP were also significantly correlated in these
patients (r  0.55; P  0.03).
Changes in biochemical parameters after
treatment
Mean plasma cortisol concentration was 0.18  0.18
mol/liter in the 12 patients who were followed after sur-
gical treatment. Changes of all studied biochemical pa-
rameters during remission of the disease are shown in Fig.
1. Remission was associated with a significant increase in
mean sclerostin levels (from121.4 46.5 to 175.8 78.5
pg/ml; P 0.003). Similarly, P1NP levels increased from
31.7 18.2 to 94.2 92.2 ng/ml (P 0.037), and CTX
levels increased from 134.2  44 to 409.2  285 pg/ml
(P  0.005). Plasma FGF23 levels also increased during
biochemical remission from 44.2  12.2 to 84.0  58.8
pg/ml (P  0.017). Serum creatinine and plasma PTH
concentrations,whichmayaffect circulating sclerostindid
not change significantly (68.8  14.7 to 71.8  14.1
mol/liter,P0.59; and4.92.3 to4.32.1pmol/liter,
P  0.60, respectively).
The median time of blood sampling
after surgical treatment was 3 months
(range 1 wk to 18 months). There was
a positive correlation between the per-
cent changes in plasma sclerostin levels
and time of surgery (r  0.68; P 
0.015). There was no correlation be-
tween sclerostin levels and changes of
bone turnover markers.
Discussion
Since its discovery a decade ago, scleros-
tin has emerged as a key negative regula-
tor of bone formation, and glucoco-
rticoids were reported to stimulate the
expression of the SOST gene, which en-
codessclerostin (3).Contrary tothis find-
ing, we show here that plasma sclerostin
levels are significantly decreased in pa-
tients with endogenous hypercortisolism
and increase after surgical treatment and
achievement of clinical and biochemical
remission.
In bone, sclerostin is exclusively pro-
duced by osteocytes (13), cells that are
directly affectedbyglucocorticoids that
promote their apoptosis (1). Recent ev-
idence suggests that glucocorticoids may also induce au-
tophagy in osteocytes (14) and/or may increase oxidative
stress (15). We, therefore, propose that the decreased
sclerostin levels of patients with hypercortisolism are due
to decreases in osteocyte function and/or number rather
than to a direct, inhibitory, effect of glucocorticoids on
sclerostin production. The increases in sclerostin levels
during biochemical remission may be due either to the
recovery of the function of the osteocytes after the cessa-
tion of themetabolic stress or to an increase in the number
of osteocytes after the removal of the apoptotic effect of
glucocorticoids.
To further explore this notion,wemeasured circulating
FGF23 in our patients before and after treatment. FGF23
is also produced by osteocytes, but its production is not
affected by glucocorticoids (3). It can, therefore, be con-
sidered as an independent parameter of the function
and/or number of osteocytes. The observed significant in-
creases in the levels of FGF23 after treatment strongly
support the hypothesis that the increases in sclerostin lev-
els represent a restoration of osteocyte numbers and/or
function. Consistent with this hypothesis is also the ob-
served increase in the biochemical markers of bone turn-
FIG. 1. Mean (SEM) levels of biochemical markers of bone turnover, sclerostin, and FGF23 in
patients with endogenous hypercortisolism at baseline (black bars) and during biochemical
remission (gray bars). *, P  0.05.
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over. Improvement in osteocyte number and/or function
may be responsible for the reversibility of the fracture risk
after discontinuation of glucocorticoid therapy (16).
Bone loss after the exogenous administration of gluco-
corticoids is biphasic with an initial rapid phase occurring
during the first months of treatment followed by a pro-
longed phase of much slower bone loss. It has been pos-
tulated that during the initial phase, an imbalancebetween
bone resorption and bone formation, in favor of resorp-
tion, is the predominant pathogenetic factor for bone loss,
whereas during the second, chronic, phase, reduced bone
formation and osteocyte apoptosis are the main determi-
nants of bone strength (17). Our findings in patients with
chronic endogenous hypercortisolism are consistent with
this sequence of events. Thus, in the presence of chronic
glucocorticoid excess, sclerostin does not seem to affect
bone formation, but its values in blood may be a measure
of the function and/or number of osteocytes. However,
sclerostin may very well be directly involved in the initial
phase of bone loss induced by glucocorticoids. This could
not be studied in our patients, but we previously showed
that treatment of a patient with sclerostin deficiency with
prednisone reduced both resorption and formationmark-
ers, and we suggested that sclerostin plays an important
role in the modulation of bone resorption by glucocorti-
coids, whereas it does not affect their action on bone for-
mation (18). Furthermore, mice treated with dexametha-
sone were protected from glucocorticoid-induced bone
loss, when they were simultaneously treated with a neu-
tralizing antibody against sclerostin (7). In these mice, the
protective effect of the sclerostin antibodywasmainly due
to the stabilization of bone resorption, with no evident
effect on bone formation. Sclerostin is thought to act
predominantly as an inhibitor of bone formation, but a
recent study has shown that sclerostin can also stimu-
late osteoclast differentiation and function by a
RANKL-mediated mechanism in osteocytes (19). In ad-
dition, inhibition of RANKL by osteoprotegerin re-
duces the rate of osteocyte apoptosis in glucocorticoid-
treated mice (20). Thus, although we found no evidence
for a role of sclerostin in glucocorticoid-induced sup-
pression of bone formation during longstanding endog-
enous hypercortisolism, sclerostinmay play a role in the
early phase of glucocorticoid-induced bone loss. Addi-
tional studies are needed to address these questions.
In conclusion, in this study,we found that patientswith
endogenous hypercortisolism have decreased circulating
sclerostin levels, which increase during biochemical re-
mission of the disease, and we propose that these changes
in sclerostin levels are due to the detrimental effect of glu-
cocorticoids on osteocytes rather than to a direct effect of
glucocorticoids on sclerostin synthesis.
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